Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
DLBCL
R-CHOP
cost-effectiveness analysis
lymphoma
pola-R-CHP
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
26
04
2023
received:
01
02
2023
accepted:
05
05
2023
medline:
18
8
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
We evaluated the cost-effectiveness of frontline polatuzumab vedotin-R-CHP (pola-R-CHP) treatment for patients with diffuse large B-cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX trial. Outcomes were measured in incremental cost-effectiveness ratios (ICERS) with a willingness-to-pay (WTP) threshold of €80 000/quality-adjusted life-years (QALY). Assuming, 69.6% 5-year PFS with pola-R-CHP and 62.6% 5-year PFS with R-CHOP, the addition of polatuzumab vedotin resulted in an additional 0.52 life-years and an incremental 0.65 QALYs but €31 988 additional cost. Based on this, pola-R-CHP was cost-effective (€49 238/QALY) at a WTP of €80 000/QALY. The cost-effectiveness of pola-R-CHP is highly dependent on its long-term outcomes and cost. Our analysis is limited by the fact that the long-term outcomes of pola-R-CHP are unknown at this time.
Substances chimiques
polatuzumab vedotin
KG6VO684Z6
Antibodies, Monoclonal
0
Immunoconjugates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
771-775Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-63.
Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, et al. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 2022;140(25):2697-708.
Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Cost-effectiveness analysis of frontline Polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2022:JCO2200478;41:1577-89.
Carias C, Chesson HW, Grosse SD, Li R, Meltzer MI, Miller GF, et al. Recommendations of the second panel on cost effectiveness in health and medicine: a reference, not a rule book. Am J Prev Med. 2018;54(4):600-2.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640-54.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-308.
Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of Axicabtagene Ciloleucel (Axi-Cel) in patients (pts) with refractory large B-cell lymphoma (LBCL). Blood. 2021;138:1764.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42.
Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among medicare patients. Leuk Lymphoma. 2018;59(12):2880-7.
Hill BT, Rybicki L, Bolwell BJ, Smith S, Dean R, Kalaycio M, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol. 2011;152(5):561-9.
Hevér N, Balogh O. The German approach to cost-effectiveness analysis in health care. Society and Economy. 2013;35(4):551-72.
Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929-35.
LAUER-Taxe Online-Database 2016 from Lauer-Fischer GmbH. WEBAPO® InfoSystem. Available from: https://www.cgm.com/deu_de/produkte/apotheke/lauer-taxe.html. Accessed 9 November 2022.
Grochtdreis T, Dams J, König H-H, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933-44.
Omidvari AH, Lansdorp-Vogelaar I, de Koning HJ, Meester RGS. Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. PLoS One. 2021;16(7):e0253893.